O slideshow foi denunciado.
Utilizamos seu perfil e dados de atividades no LinkedIn para personalizar e exibir anúncios mais relevantes. Altere suas preferências de anúncios quando desejar.

20150924 smb cristal therapeutics jeroen tonnaer

542 visualizações

Publicada em

Presentation Science Meets Business @ Health Valley From Molecule to Business 20150924

Publicada em: Saúde e medicina
  • Seja o primeiro a comentar

  • Seja a primeira pessoa a gostar disto

20150924 smb cristal therapeutics jeroen tonnaer

  1. 1. From Molecule to Business Health Valley/SMB September 24, 2015 Nijmegen CriPec® Nanomedicines for Superior Therapeutic Performance Dr. Jeroen Tonnaer, CBO
  2. 2. 2 Introduction • Pharmaceutical company developing nanomedicines • Founded in April 2011 • Located in Maastricht, The Netherlands • Headcount: 10 fte • Private - VC funded: 2
  3. 3. 3 CriPec® Nanomedicines Improved efficacy and tolerability CriPec® improves the therapeutic profile of drugs as a result of: • Extended systemic circulation • Improved disposition over the body • Active or passive targeting to tissue, cellular and molecular targets • Tuneable and timely release 3
  4. 4. CriPec® polymer drug linker entrapment of drug, so inactive release native drug & degradation NP coupling of drug drug linker CriPec® polymer incl. linker drug lactic acid Unique CriPec® Platform Transiently stable nanomedicines 4 PATENT PROTECTED BY 5 PATENT FAMILIES
  5. 5. range of therapeutic agents (small molecules - peptides) biodegradable and safe fragments multiple administration routes controllable size from 30 nm up to 100 nm X surface functionalisation for cellular and molecular targeting ease of manufacturing customised drug release Unique Features of CriPec® Highly flexible nanomedicinal platform 5
  6. 6. Therapeutic effect CriPec® Docetaxel Breast xenograft model 6 s.c. MDA-MB-231 xenografts in nude mice (n=8±SD) 0 14 28 42 56 0 250 500 750 1000 1250 1500 single dose vehicle Taxotere 60 mg/kg CriPec docetaxel 60 mg/kg time (days) tumourvolume(mm3 ) s.c. MDA-MB-231 xenografts in nude mice (n=10±SD) 0 14 28 42 56 0 250 500 750 1000 1250 1500 1750 2000 vehicle Taxotere 30 mg/kg CriPec docetaxel 125 mg/kg single dose time (days) tumourvolume(mm3 )
  7. 7. Unique Opportunity • CriPec® is unique and competitive nanotechnology platform that enables development of multiple (targeted) products • CriPec® boosts efficacy and improves tolerability • Applicable in disease areas with high unmet medical need • First product started clinical development July 2015 • Attractive co-development potential • CriPec® platform & products are protected by 5 patent families 7
  8. 8. Value Drivers • Clinical - Clinical phase I: safety of CriPec® docetaxel and PK profile - Clinical phase IIa/IIb: efficacy of CriPec® docetaxel • Platform - In house PoC for CriPec® peptide, CriVac® antigen, and CriPec® active targeting (ATN) - A commercial viable, robust and generic cGMP-manufacturing process • Business - Successful feasibility studies for partners - Successful (license) partnerships (full (co-)development programs) 8
  9. 9. Pipeline 9 indication discovery PoC preclinical phase I phase IIa Proprietary programs CriPec® docetaxel solid tumours CriPec® dexamethasone inflammatory CriPec® active targeting solid tumours CriPec® oligonucleotides various Collaborative programs CriPec® peptides solid tumours CriVac® antigens solid tumours achieved ongoing
  10. 10. General BD&L Considerations DO: • Understand the candidate licensee’s strategy and needs - Unlikely our opportunity will move the company’s strategy - Look for gaps we can fill - Ask for specific guidance on what the company is looking for • Appeal to licensee’s core values, for example: - Cutting-edge science - Novel medicines that make a difference • Demonstrate how our offering fits into their pipeline or research framework 10
  11. 11. General BD&L Considerations DON’T: • Forget that there is a fundamental difference between research (which advances technology without being constrained by business requirements) and product development (which must satisfy customer needs with safe, proven therapies that are competitive and cost-effective) • Expect to successfully license technology with no proven customer or market fit 11
  12. 12. CriPec® Docetaxel BD&L Considerations • Concept of disruptive vs. incremental innovation • Understanding stakeholders’ innovation preference • Multinationals • Regional players (e.g. Asian Pharma) • Adopters (e.g. innovative generics manufacturers) • Drafting CriPec® docetaxel licensing strategy • Analysis of market gaps in oncology • New application areas for CriPec® docetaxel • Competitive landscape (USPs vs. taxotere & NM competition) • Stakeholders landscape • Valuation of CriPec® docetaxel • Outline licensing deal 12
  13. 13. www.cristaltherapeutics.com

×